Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)

ClinicalTrials.gov ID: NCT03912532

Public ClinicalTrials.gov record NCT03912532. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of NGM282 Administered for 24 Weeks for the Treatment of Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study identification

NCT ID
NCT03912532
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
NGM Biopharmaceuticals, Inc
Industry
Enrollment
171 participants

Conditions and interventions

Interventions

  • NGM282 Biological
  • Placebo Other

Biological · Other

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 15, 2019
Primary completion
Mar 3, 2021
Completion
Mar 28, 2021
Last update posted
Jul 2, 2025

2019 – 2021

United States locations

U.S. sites
36
U.S. states
15
U.S. cities
31
Facility City State ZIP Site status
NGM Clinical Study Site Chandler Arizona 85224
NGM Clinical Study Site 814 Tucson Arizona 85712
NGM Clinical Study Site 816 Tucson Arizona 85712
NGM Clinical Study Site North Little Rock Arkansas 72117
NGM Clinical Study Site Fresno California 93720
NGM Clinical Study Site La Jolla California 92093
NGM Clinical Study Site Los Angeles California 90036
NGM Clinical Study Site Los Angeles California 90057
NGM Clinical Study Site Poway California 92064
NGM Clinical Study Site Rialto California 92377
NGM Clinical Study Site Boca Raton Florida 33434
NGM Clinical Study Site Lakewood Rch Florida 34211
NGM Clinical Study Site Port Orange Florida 32127
NGM Clinical Study Site Sarasota Florida 34240
NGM Clinical Study Site The Villages Florida 32162
NGM Clinical Study Site Chicago Illinois 60611
NGM Clinical Study Site Baton Rouge Louisiana 70809
NGM Clinical Study Site Baltimore Maryland 21202
NGM Clinical Study Site Ann Arbor Michigan 48109
NGM Clinical Study Site Flowood Mississippi 39232
NGM Clinical Study Site Jackson Mississippi 39216
NGM Clinical Study Site Kansas City Missouri 64131
NGM Clinical Study Site St Louis Missouri 63104
NGM Clinical Study Site New York New York 10029
NGM Clinical Study Site Durham North Carolina 27708
NGM Clinical Study Site Fayetteville North Carolina 28304
NGM Clinical Study Site Germantown Tennessee 38138
NGM Clinical Study Site Hermitage Tennessee 37076
NGM Clinical Study Site Austin Texas 78757
NGM Clinical Study Site 845 Edinburg Texas 78539
NGM Clinical Study Site Edinburg Texas 78539
NGM Clinical Study Site Houston Texas 77030
NGM Clinical Study Site San Antonio Texas 78229
NGM Clinical Study Site San Antonio Texas 78233
NGM Clinical Study Site Richmond Virginia 23226
NGM Clinical Study Site Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03912532, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 2, 2025 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03912532 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →